• Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
Wednesday, November 18, 2026
No Result
View All Result
Subscribe Now
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
The Insight Post
  • Home
  • Insight
  • Blog
  • Business
  • Entertainment
  • Health
  • Politics
  • Shop
    • Gift Shop
    • Value Shop
    • Store
    • Bargain Shop
    • Discount
  • Sports
  • Tech
  • Travel
  • USA
    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Mary Peltola Emerges Victorious in Alaska Senate Race, Making History for Democrats

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Stranded in Conflict: Palestinians Navigate the Tenuous Balance of War and Peace Amid Ceasefire Efforts

    Trump Administration Revokes Pay Increase for Head Start Educators

    Trump Administration Revokes Pay Increase for Head Start Educators

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Unexpected Triumph: Gay Candidates Achieve Unforeseen Victories in Challenging Races

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Microsoft Outlook Experiences Prolonged Outage Affecting Users Nationwide

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    Gunfire Erupts in D.C.: Authorities Search for Suspect Amid Rising Concerns Over Public Safety

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    LAUSD Takes Strong Action Against Hate Speech Following Racial Slur Incidents

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Beloved Former Los Angeles Times Columnist Steve Harvey Passes Away at 80

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

    Exploring Diversity: ‘Ten Lives’ Showcases the Varied Economic Journeys of Americans

  • Video
  • World
    • Asia
    • Africa
    • South America
    • North America
    • Europe
    • Oceania
No Result
View All Result
No Result
View All Result
Home Science

FDA Rejects MDMA For PTSD. What Does This Mean For Future Psychedelic Medications? : ScienceAlert

by Theinsightpost
August 14, 2024
in Science
0 0
0
FDA Rejects MDMA For PTSD. What Does This Mean For Future Psychedelic Medications? : ScienceAlert

Drugmaker Lykos Therapeutics announced on Aug. 9, 2024, that the Food and Drug Administration declined to approve the company’s application for the use of MDMA-assisted therapy in the treatment of post-traumatic stress disorder. It is the first such decision issued on a psychedelic drug application.

Many investors and researchers have been predicting a psychedelics boom, with MDMA being just the first of a number of psychedelics in the drug development pipeline.

The FDA’s decision has disappointed psychedelic therapy advocates, and the stock prices of psychedelic industry leaders tumbled with the announcement. But the FDA did make recommendations as to how the application could be improved in such a way that MDMA might receive future approval.

Yet another setback came days later when the journal Psychopharmacology retracted three papers related to MDMA-assisted therapy, citing “protocol violations amounting to unethical conduct,” particularly in one clinical trial.

The Conversation asked drug researcher Benjamin Y. Fong from Arizona State University about what the FDA’s decision entails and what it means for the future of psychedelic medications.

What is MDMA, and what types of conditions could it treat?

MDMA, or midomafetamine, is known colloquially as “molly” or “ecstasy.” It is technically an amphetamine – like the drug in the attention-deficit/hyperactivity disorder medication Adderall – but MDMA is often categorized as a psychedelic.

It is considered to be more pleasure-inducing than other amphetamines, and for this reason it has been a popular party drug. Some researchers call MDMA an “empathogen,” or a “feeling enhancer.”

While MDMA is currently a Schedule I drug – meaning that the Drug Enforcement Administration considers it to be highly dangerous with no accepted medical use – a number of clinical trials point to the benefits of using MDMA in combination with talk therapy for patients suffering from PTSD.

The FDA granted “breakthrough therapy” status to MDMA-assisted therapy in 2017, which sped along its development and review.

PTSD affects between 9 million to 13 million people annually in the U.S., and no novel treatments for the condition have been developed in the past 20 years.

Lykos Therapeutics filed an application for FDA approval of its version of MDMA-assisted therapy for PTSD in February 2024. In it, the drug is paired with a type of psychotherapy intended to bring out a patient’s “inner healing intelligence“, which Lykos defines as “a person’s innate capacity to heal the wounds of trauma.”

frameborder=”0″ allow=”accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share” referrerpolicy=”strict-origin-when-cross-origin” allowfullscreen>

Why did the FDA decline approval of Lykos’ MDMA-assisted therapy?

In June 2024, an FDA advisory committee voted overwhelmingly against the idea that the relevant clinical trials had proved the efficacy of MDMA for the treatment of PTSD.

Just as decisively, the panel also voted against the idea that the benefits had been shown to outweigh the risks, such as increased blood pressure and abuse potential.

At that time, the advisory committee took issue with several aspects of Lykos’ application. First, it noted the problem of “functional unblinding,” which is the fact that most people participating in the trial would know if they are on a powerful psychoactive substance or not, biasing the results.

This is a problem for any psychoactive medication, and Lykos critics believe the company should have followed FDA guidance that it use an “active placebo” – a placebo that also has psychoactive effects – for comparison in its previous clinical trials.

The panel also raised questions about the form of psychotherapy used alongside MDMA, as well as ethical concerns about various forms of misconduct in Lykos’ trials. In one of the company’s studies, a participant reported sexual misconduct by the therapists involved.

The FDA is not bound by the votes of such advisory bodies, but it typically follows their guidance. So the decision on Friday was no great surprise.

What does the FDA’s decision mean for the future of MDMA?

The FDA requested an additional phase 3 study, the stage of clinical trials that rigorously demonstrates the safety and efficacy of a particular treatment in comparison to standard treatment.

Lykos stated that it will request a reconsideration of the decision and discuss the FDA’s recommendations with the agency to ensure that the company is on the right path forward.

Lykos CEO Amy Emerson, who called the decision “deeply disappointing,” says she believes it will take “several years” to conduct the new trial.

But with the journal Psychopharmacology’s retraction of three papers related to this work, Lykos has a difficult road ahead of it.

How might this decision affect other psychedelic drugs’ approval?

One prominent psychedelics company, Compass Pathways, is generally considered next in line for FDA approval of a psychedelic drug, with phase 3 clinical trials for its synthetic psilocybin well underway. There are other companies preparing for phase 3 trials of their own proprietary compounds.

In the wake of the advisory panel judgment in June, Compass noted that it is not pairing its drug with therapy in the way Lykos has. Another company claimed that it has a “better trial design that is more in line with FDA guidance.”

Other psychedelics companies clearly believe they can still succeed where Lykos has not.

Do psychedelics face unique challenges?

The FDA’s decision was more about Lykos’ specific approach than an outright rejection of psychedelics for therapeutic use.

But psychedelic drug development is a fraught process by nature. The drugs involved induce a severely altered state that puts people in a vulnerable position. Some people in the industry that I have spoken to believe it’s nearly impossible to avoid accusations of impropriety, given the nature of the experience.

Most research also pairs psychedelic drugs with some form of therapy or facilitation, and as the FDA has made clear, its role is to assess drugs, not the psychotherapies that might go along with them.

The interaction between the drugs and the human element involved in the treatment is the subject of some debate. Lykos’ missteps in its application shine a light on some of the ways that companies involved in psychedelic drug development face unique obstacles on the way to FDA approval.

Benjamin Y. Fong, Honors Faculty Fellow, Associate Teaching Professor, and Associate Director of the Center for Work & Democracy, Arizona State University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

ShareTweetSend
Previous Post

‘Nobody likes to see war’: Lebanese Manitobans cautious amid travel warnings – Winnipeg

Next Post

Invest in Courageous, Progressive Journalism

Related News

Groundbreaking Electric Comb Promises Hair Regrowth in Mice Within Four Weeks, Paving the Way for Future Hair-Loss Solutions
Science

Groundbreaking Electric Comb Promises Hair Regrowth in Mice Within Four Weeks, Paving the Way for Future Hair-Loss Solutions

November 18, 2026
Miniature LSD Doses Administered in Rapid Succession Show Antidepressant Potential in Mice: Exploring the Impact of Timing vs. Tolerance
Science

Miniature LSD Doses Administered in Rapid Succession Show Antidepressant Potential in Mice: Exploring the Impact of Timing vs. Tolerance

November 14, 2026
Investigation Underway: Experts Seek Answers Behind Sudden Brooklyn Building Collapse
Science

Investigation Underway: Experts Seek Answers Behind Sudden Brooklyn Building Collapse

November 12, 2026
Preserve the Unseen: The Essential Role of Parasites in Ecosystems
Science

Preserve the Unseen: The Essential Role of Parasites in Ecosystems

November 11, 2026
Next Post
Invest in Courageous, Progressive Journalism

Invest in Courageous, Progressive Journalism

Discussion about this post

Subscribe To Our Newsletters

    Customer Support


    1251 Wilcrest Drive
    Houston, Texas
    77042 USA
    Call-832.795.1420
    e-mail – news@theinsightpost.com

    Subscribe To Our Newsletters

      Categories

      • Africa
      • Africa-East
      • African Sports
      • American Sports
      • Arts
      • Asia
      • Australia
      • Business
      • Business Asia
      • Business- Africa
      • Canada
      • Defense
      • Education
      • Egypt
      • Energy
      • Entertainment
      • Europe
      • European Soccer
      • Finance
      • Germany
      • Ghana
      • Health
      • Insight
      • International
      • Investing
      • Japan
      • Latest Headlines
      • Life & Living
      • Markets
      • Mobile
      • Movies
      • New Zealand
      • Nigeria
      • Politics
      • Scholarships
      • Science
      • South Africa
      • South America
      • Sports
      • Tech
      • Travel
      • Travel-Africa
      • UK
      • USA
      • Weather
      • World
      No Result
      View All Result

      Recent News

      Vintage Photo of Robert Pattinson and Daniel Craig Gains New Significance Amid Bond Casting Developments

      Vintage Photo of Robert Pattinson and Daniel Craig Gains New Significance Amid Bond Casting Developments

      November 18, 2026
      Top 7 Retirement Threats and Effective Strategies to Navigate Them

      Top 7 Retirement Threats and Effective Strategies to Navigate Them

      November 18, 2026
      Charting the Future: Unveiling the TEFCA 2026-2027 Workplan and Innovative Monthly Metrics

      Charting the Future: Unveiling the TEFCA 2026-2027 Workplan and Innovative Monthly Metrics

      November 18, 2026
      Inevitable Buyer’s Remorse Looms Over Midterm Elections

      Inevitable Buyer’s Remorse Looms Over Midterm Elections

      November 18, 2026
      • Home
      • Advertise With Us
      • About Us
      • Corporate
      • Consumer Rewards
      • Forum
      • Privacy Policy
      • Social Trends

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      Welcome Back!

      Login to your account below

      Forgotten Password?

      Retrieve your password

      Please enter your username or email address to reset your password.

      Log In

      Add New Playlist

      We are using cookies to give you the best experience on our website.

      You can find out more about which cookies we are using or switch them off in .

      No Result
      View All Result
      • Home
      • Insight
      • Blog
      • Business
      • Entertainment
      • Health
      • Politics
      • Shop
        • Gift Shop
        • Value Shop
        • Store
        • Bargain Shop
        • Discount
      • Sports
      • Tech
      • Travel
      • USA
      • Video
      • World
        • Asia
        • Africa
        • South America
        • North America
        • Europe
        • Oceania

      Theinsightpost ©2026 | All Rights Reserved. Theinsightpost is an Elnegy LLC company, registered in Texas, USA

      The Insight Post
      Powered by  GDPR Cookie Compliance
      Privacy Overview

      This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

      Strictly Necessary Cookies

      Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

      Cookie Policy

      More information about our Cookie Policy